Mark Stein

11PUBLICATIONS
167CO-AUTHORS
Molecular targetsCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Jun 12, 2025
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Michael A Liu, Rohit Raghunathan, Karie Runcie

|Jun 01, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein, Armelle Vinceneux, Debbie Robbrecht

|Feb 24, 2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.

Miya B Hugaboom, Lena V Wirth, Kelly Street

|Jan 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Jason J Luke, Randy F Sweis, J Randolph Hecht

Pageof 2

Frequent Collaborators

4 joint publications

Naomi Balzer-Haas

3 joint publications

Opeyemi A Jegede

3 joint publications

David Braun

3 joint publications

Thomas Denize